Analysts Anticipate Krystal Biotech Inc (NASDAQ:KRYS) Will Post Earnings of -$0.31 Per Share

Share on StockTwits

Wall Street analysts predict that Krystal Biotech Inc (NASDAQ:KRYS) will announce earnings per share (EPS) of ($0.31) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Krystal Biotech’s earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.29). Krystal Biotech reported earnings of ($0.22) per share during the same quarter last year, which suggests a negative year over year growth rate of 40.9%. The business is scheduled to announce its next quarterly earnings report on Monday, August 5th.

On average, analysts expect that Krystal Biotech will report full year earnings of ($1.45) per share for the current year, with EPS estimates ranging from ($1.74) to ($1.18). For the next financial year, analysts expect that the firm will post earnings of ($1.52) per share, with EPS estimates ranging from ($1.83) to ($0.94). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Krystal Biotech.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Tuesday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04.

A number of equities research analysts have recently weighed in on the stock. Guggenheim assumed coverage on shares of Krystal Biotech in a research note on Thursday, May 30th. They issued a “buy” rating and a $31.57 price target on the stock. HC Wainwright raised their price target on shares of Krystal Biotech from $32.00 to $38.00 and gave the company a “positive” rating in a research note on Friday, May 24th. William Blair restated a “buy” rating on shares of Krystal Biotech in a research note on Monday, June 24th. Zacks Investment Research downgraded shares of Krystal Biotech from a “hold” rating to a “sell” rating in a research note on Friday, March 22nd. Finally, Cowen reiterated a “buy” rating on shares of Krystal Biotech in a research report on Monday, May 6th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $49.83.

KRYS stock opened at $44.38 on Wednesday. The company has a current ratio of 33.28, a quick ratio of 33.28 and a debt-to-equity ratio of 0.03. Krystal Biotech has a 12 month low of $14.30 and a 12 month high of $48.31. The company has a market cap of $757.38 million, a price-to-earnings ratio of -45.75 and a beta of 0.98. The firm has a 50-day moving average price of $33.63.

Hedge funds have recently added to or reduced their stakes in the stock. Knott David M acquired a new stake in shares of Krystal Biotech in the 4th quarter valued at $31,000. New York State Common Retirement Fund bought a new stake in Krystal Biotech in the fourth quarter valued at approximately $159,000. Citigroup Inc. bought a new stake in shares of Krystal Biotech during the fourth quarter worth $214,000. TD Asset Management Inc. acquired a new position in Krystal Biotech during the first quarter worth $268,000. Finally, MYDA Advisors LLC acquired a new stake in Krystal Biotech in the first quarter valued at $296,000. 46.05% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.

See Also: What is a Fiduciary?

Get a free copy of the Zacks research report on Krystal Biotech (KRYS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

JPMorgan Chase & Co. Increases AvalonBay Communities  Price Target to $224.00
JPMorgan Chase & Co. Increases AvalonBay Communities Price Target to $224.00
Brightsphere Investment Group  Lifted to “Hold” at Zacks Investment Research
Brightsphere Investment Group Lifted to “Hold” at Zacks Investment Research
PLDT  Rating Lowered to Hold at Zacks Investment Research
PLDT Rating Lowered to Hold at Zacks Investment Research
AtriCure  Stock Rating Lowered by Northland Securities
AtriCure Stock Rating Lowered by Northland Securities
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine


 
© 2006-2019 Zolmax.